News

Filter

Current filters:

EisaiTargretin

Valeant Pharma buys US rights to Eisai's Targretin for $65 million upfront

21-02-2013

Canada's Valeant Pharmaceuticals International (TSX: VRX) says that it has acquired US rights for Targretin…

EisaiLicensingNorth AmericaOncologyPharmaceuticalTargretinValeant Pharmaceuticals

Eisai licenses bexarotene to Minophagen forJapan; Roche opts for Invida for Korean marketing

04-04-2011

Japanese drug major Eisai (TYO: 4532) has granted a license Minophagen Pharmaceutical, based in Tokyo,…

Asia-PacificbexaroteneEisaiInvidaLicensingMinophagenOncologyPharmaceuticalRocheTargretin

Ligand to settle dispute with Salk Institute

15-09-2008

USA-based Ligand Pharmaceuticals has entered a settlement agreement in its dispute with the Salk Institute…

bexaroteneEisaiTargretinWyeth

Japan's Eisai spreads its wings with $325 million acquisition of USA's Morphotek

02-04-2007

In what it describes as a "dramatic leap towards biologic therapeutics," Japan's fourth-largest pharmaceutical…

AlitretinoinAriceptbexaroteneDenileukin DiftitoxdonepezilEisaiOntakPanretinTargretin

Ligand finalizes sale of oncology line to Eisai

06-11-2006

San Diego, USA-based Ligand Pharmaceuticals says it has completed the sale of its oncology product line…

AlitretinoinbexaroteneDenileukin DiftitoxEisaiOntakPanretinTargretin

COMPANY SPOTLIGHT

Menarini

Back to top